|Slideshows|September 30, 2019

Psychiatry Update: Parental History, Pediatric Bipolar Disorder, and More

Parental history shapes pediatric bipolar in offspring, no evidence for deterioration in neurocognitive functioning, clinical course predictors identified-these are some of the latest findings in bipolar disorder research.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

Categories vs Dimensions: Wave or Particle?

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa

July 29th 2026

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

Brain Trust: Addiction Pharmacotherapy in Bipolar Disorder, Rethinking Comorbidity With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 1st 2026

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

ByJoseph F. Goldberg, MD,David Dunner, MD, FACPsych

June 26th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychiatry Update: Parental History, Pediatric Bipolar Disorder, and More

Related Content

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

Categories vs Dimensions: Wave or Particle?

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

Brain Trust: Addiction Pharmacotherapy in Bipolar Disorder, Rethinking Comorbidity With Michael J. Ostacher, MD, MPH

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

New Ingrezza Data Shows Improved Quality of Life and Daily Functioning in Tardive Dyskinesia

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety